Health

Mayo Clinic and Alexandria Venture Investments contributed to a $55m extension that boosted the molecular drug developer's overall funding to $143m.

A range of new and existing backers have added $45m to ViaCyte’s series D round, which now stands at more than $115m.

Alexandria Venture Investments has taken part in a series B round for the cytokine immunotherapy developer following a $35m series A.

Berkshire Hathaway led a second tranche of a series G round, raised by Nubank, a Tencent-backed virtual bank based in Brazil, at a $30bn valuation.

Transcarent has raised $58m from Bayer and Merck, while Nvidia has bought DeepMap, one of its portfolio companies also backed by Bosch.

The immuno-oncology therapy developer has amassed at least $190m of overall funding since emerging out of Stanford University.

The immuno-oncology therapy developer has amassed at least $190m of overall funding following a series B round backed by Lilly Asia Ventures.

The Tata unit has reportedly bought a 55% stake in the Intel Capital-backed digital pharmacy operator, which was valued at $200m as of mid-2019.

Barda Ventures, the investment unit of HHS’s Biomedical Advanced Research and Development Authority, has committed a minimum of $50m.

Blockchain game developer Mythical Games pulled in $75m while enterprise software developer Morning Consult reached a unicorn valuation in an Advance Venture Partners-led round.

Roivant spinoff Datavant is joining forces with medical data technology peer Ciox Health, which counts Merck & Co as an investor.